Saillard Colombe, Zafrani Lara, Darmon Michael, Bisbal Magali, Chow-Chine Laurent, Sannini Antoine, Brun Jean-Paul, Ewald Jacques, Turrini Olivier, Faucher Marion, Azoulay Elie, Mokart Djamel
Haematology Department, Institut Paoli Calmettes, 232 Boulevard Sainte Marguerite, 13009, Marseille Cedex 09, France.
Medical Intensive Care Unit, Saint-Louis University Hospital, AP-HP, Paris, France.
Ann Intensive Care. 2018 Apr 19;8(1):47. doi: 10.1186/s13613-018-0394-6.
Neutropenic enterocolitis (NE) is a diagnostic and therapeutic challenge associated with high mortality rates, with controversial opinions on its optimal management. Physicians are usually reluctant to select surgery as the first-choice treatment, concerns being raised regarding the potential risks associated with abdominal surgery during neutropenia. Nevertheless, no published studies comforted this idea, literature is scarce and surgery has never been compared to medical treatment. This review and meta-analysis aimed to determine the prognostic impact of abdominal surgery on outcome of neutropenic cancer patients presenting with NE, versus medical conservative treatment. This meta-analysis included studies analyzing cancer patients presenting with NE, treated with surgical or medical treatment, searched by PubMed and Cochrane databases (1983-2016), according to PRISMA recommendations. The endpoint was hospital mortality. Fixed-effects models were used. The meta-analysis included 20 studies (385 patients). Overall estimated mortality was 42.2% (95% CI = 40.2-44.2). Abdominal surgery was associated with a favorable outcome with an OR of 0.41 (95% CI = 0.23-0.74; p = 0.003). Pre-defined subgroups analysis showed that neither period of admission, underlying malignancy nor neutropenia during the surgical procedure, influenced this result. Surgery was not associated with an excess risk of mortality compared to medical treatment. Defining the optimal indications of surgical treatment is needed.Trial registration PROSPERO CRD42016048952.
中性粒细胞减少性小肠结肠炎(NE)是一种诊断和治疗上的挑战,死亡率很高,对于其最佳治疗方法存在争议。医生通常不愿选择手术作为首选治疗方法,因为担心中性粒细胞减少期间腹部手术会带来潜在风险。然而,尚无已发表的研究支持这一观点,相关文献稀少,且从未将手术与药物治疗进行比较。本综述和荟萃分析旨在确定腹部手术对患有NE的中性粒细胞减少癌症患者的预后影响,并与药物保守治疗进行对比。根据PRISMA建议,该荟萃分析纳入了通过PubMed和Cochrane数据库(1983 - 2016年)检索到的分析患有NE的癌症患者接受手术或药物治疗的研究。终点指标是医院死亡率。使用固定效应模型。该荟萃分析纳入了20项研究(385例患者)。总体估计死亡率为42.2%(95%置信区间 = 40.2 - 44.2)。腹部手术与较好的预后相关,比值比为0.41(95%置信区间 = 0.23 - 0.74;p = 0.003)。预定义亚组分析表明,入院时间、潜在恶性肿瘤以及手术过程中的中性粒细胞减少均未影响这一结果。与药物治疗相比,手术并未增加死亡风险。需要确定手术治疗的最佳适应症。试验注册号:PROSPERO CRD42016048952